EdiGene, Inc. announced the Center for Drug Evaluation of China National Medical Products Administration has approved the company’s Investigational New Drug (IND) application for ET-01, an investigational CRISPR/Cas 9 gene-editing therapy for patients with transfusion dependent β-thalassemia.
[EdiGene, Inc.]
0